Self-Assessment Post-Test

SELF-ASSESSMENT POST-TEST There are no fees for participating and receiving CME credit for this activity. During the period of November 2004 through November 30, 2005, participants must: 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. Challenges in the Treatment of Advanced Symptomatic Prostate Cancer Patients 1. In the early history of prostate cancer treatment, both medical and surgical adrenalectomies were abandoned because of ________: a. Poor objective response rates b. High morbidity c. Side effects such as lethargy, ankle edema, and nausea d. All of the above 2. In the first few weeks after initiating therapy, concerns with luteinizing hormone-releasing hormone (LHRH) agonist therapy include ________: a. An initial surge in testosterone levels b. Tumor flare c. Increased pain d. All of the above 3. The Southwest Oncology Group (SWOG) study INT 0036 and the findings of the European Organization of Research indicated that treating patients with combined androgen blockade is advantageous. a. True b. False 4. The conclusions of the SWOG study INT 0036, showing increased survival with use of combined androgen blockade, has been upheld in every study conducted since. a. True b. False 5. In a meta-analysis, men with higher levels of testosterone have been found to have a ________ risk of prostate cancer. a. Greater b. Lesser 6. The term __________ refers to a transient increase in luteinizing hormone level and resulting stimulation of follicle-stimulating hormone (FSH), dihydrotestosterone, and testosterone. a. Flare b. Surge 7. The most serious manifestation of _________ is spinal cord compression from expansion of spinal metastasis resulting in paraplegia, quadriplegia, and, in some patients, death. a. Flare b. Surge 8. Which of the following is a false statement regarding treatment with gonadotropin-releasing hormone (GnRH) antagonists? a. Most men treated with GnRH antagonists will reach castrate levels of testosterone within 8 days. b. Treatment with GnRH antagonists should be accompanied by the addition of an anti-androgen agent. c. The short time to reach castrate levels of testosterone after treatment with GnRH antagonists may provide enhanced radiosensitivity, apoptosis, and downsizing of the tumor. d. Treatment with GnRH antagonists in the neoadjuvant setting avoids the adverse effects of flare and has been shown to provide high quality of life scores. 9. In the following statements about findings of the European Phase III Study reported by Debruyne and colleagues, which statement is false? a. The most common treatment-related event in the abarelix group was asthenia. b. In the goserelin plus bicalutamide group, the most common treatment-related event was gynecomastia. c. Abarelix-treated patients showed more increase in liver function test results than the goserelin plus bicalutamide group. d. Patient survival outcomes were about the same for both experimental treatment groups. 10. While abarelix-treated patients showed more effective suppression of FSH than the LHRH agonist-treated patients, additional studies must be performed to determine whether this translates into clinical response in androgen-independent prostate cancer. a. True b. False EVALUATION FORM Challenges in the Treatment of Advanced Symptomatic Prostate Cancer Patients Project ID: 2104 ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity. VOL. 6 SUPPL. 7 2004 REVIEWS IN UROLOGY S47 Please answer the following questions by circling the appropriate rating: 5 = Outstanding; 4 = Good; 3 = Satisfactory; 2 = Fair; 1 = Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be able to: • Review the historical approaches to hormonal therapy in prostate cancer 5 • Discuss the clinical implications of disease flare 5 • Identify the challenges with LHRH agonists 5 • Discuss findings of studies related to the advantages of GnRH antagonists in locally advanced and symptomatic prostatic disease 5 OVERALL EFFECTIVENESS OF THE ACTIVITY • Was timely and will influence how I practice • Will assist me in improving patient care • Fulfilled my educational needs • Avoided commercial bias or influence 5 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 4 3 2 1 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 IMPACT OF THE ACTIVITY The information presented: (check all that apply)
Reinforced my current practice/treatment habits
Will improve my practice/patient outcomes
Provided new ideas or information I expect to use
Enhanced my current knowledge base Will the information presented cause you to make any changes in your practice? Yes___ No___ If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? (Very committed) 5 4 3 2 1 (Not at all committed) FOLLOW-UP As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:
Yes, I would be interested in participating in a follow-up survey
No, I’m not interested in participating in a follow-up survey Additional comments about this activity: If you wish to receive acknowledgment of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and FAX to: 303-790-4876. POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ REQUEST FOR CREDIT Please Print Clearly Name: Address: City/State: Phone Number: Fax Number: E-mail: Specialty: Organization: Degree: Box/Suite: Zip Code: I certify my actual time spent to complete this educational activity to be:
I participated in the entire activity and claim 2.0 credits.
I participated in only part of the activity and claim ___ credits. Signature: S48 VOL. 6 SUPPL. 7 2004 REVIEWS IN UROLOGY Date Completed: